Illumina CEO on Earnings Outlook, Buying Grail

Francis D'souza, CEO of Alumina, discusses the company's 2023 guidance, the launch of NovaSeq X, and its competitive landscape. He highlights the significant price reduction in genome sequencing and the unique features of their product. The acquisition of GRAIL and its regulatory challenges in the EU are also covered. The conversation concludes with a focus on making genomics more accessible and the goal of achieving a $100 genome.

What are the potential implications for Alumina if they are required to divest GRAIL?

What challenges does Alumina face regarding the regulatory approval of GRAIL in the EU?

How does Alumina plan to make genomics accessible to a broader audience?